Medical Technology

Seuraa
Dramatic illustration of Stryker's operations center disrupted by Iran-linked cyberattack, with error-filled screens and intact medical devices.
AI:n luoma kuva

Iran-linked hackers disrupt Stryker's network in apparent retaliation

Raportoinut AI AI:n luoma kuva

A cyberattack attributed to the Iran-aligned Handala Hack group has disrupted the Microsoft environment of medical device maker Stryker, paralyzing much of its global operations. The incident, which emerged shortly after US and Israeli airstrikes on Iran, involved data wiping across tens of thousands of computers. Stryker confirmed the attack is contained, with no impact on its critical medical devices.

Acarix AB held its Q1 2026 earnings call on May 17, where President and CEO Aamir Mahmood discussed ongoing operations despite global challenges.

Raportoinut AI

Researchers at the University of Hong Kong have developed a world-first nasal spray that delivers neurotherapeutic powder directly to the brain as first aid for ischemic stroke patients. The treatment, named NanoPowder, is designed to reduce brain damage by more than 80 per cent and improve stroke survival rates. Clinical trials are expected by 2030.

Researchers from the University of Texas at Austin and the University of Porto have created a cancer treatment using LED light and tin nanoflakes that destroys up to 92% of skin cancer cells without harming healthy tissue. This affordable alternative to traditional therapies relies on near-infrared photothermal principles. The breakthrough, published in ACS Nano, aims to make targeted cancer care more accessible worldwide.

Raportoinut AI

A man paralyzed from a diving accident has used a brain implant to control and sense another person's hand as if it were his own. The technology, developed by researchers in New York, allowed him to distinguish between objects by touch and assist another paralyzed individual. This breakthrough could aid rehabilitation and raise ethical questions about remote body control.

Tämä verkkosivusto käyttää evästeitä

Käytämme evästeitä analyysiä varten parantaaksemme sivustoamme. Lue tietosuojakäytäntömme tietosuojakäytäntö lisätietoja varten.
Hylkää